Healthcare

In a landmark development for neurodevelopmental healthcare, the U.S. Food and Drug Administration (FDA) has approved leucovorin, a folate-based medication, for the treatment of autism spectrum disorder (ASD). The decision represents a significant step forward in addressing the complex medical needs of individuals with autism, a condition that affects millions worldwide. Clinical trials demonstrated that leucovorin can improve communication, social interaction, and behavioral outcomes in certain subgroups of patients, particularly those with folate metabolism irregularities.

Anlon Healthcare’s initial public offering (IPO) made a subdued debut on the stock market, reflecting cautious investor sentiment amid prevailing market volatility. Shares opened slightly above the issue price but showed limited upward momentum, signaling a muted response from both retail and institutional participants. Analysts suggest that while the company has a solid operational foundation in the healthcare sector, broader market conditions and investor preference for more liquid or high-growth stocks may have tempered demand.

Apollo Hospitals Enterprise Ltd., one of India’s largest healthcare providers, witnessed a significant promoter stake sale valued at Rs 1,489 crore. The transaction, executed through block deals, underscores the growing appetite of institutional investors in India’s booming healthcare sector. While the offloading reduces promoter holding marginally, it provides fresh liquidity and deepens the company’s public shareholding. Analysts view the move as a strategic step to enhance financial flexibility and attract long-term investors.

Max Healthcare Institute Ltd. has reported a 17% year-on-year increase in consolidated net profit for the first quarter, reaching Rs. 345 crore, driven by robust growth in patient volumes and operational efficiency. Revenue for the quarter rose in tandem with higher occupancy rates, improved case mix, and an uptick in premium healthcare services. The performance reflects the hospital chain’s ability to leverage its expanding network, optimize costs, and tap into rising demand for advanced medical treatments.

Apollo Hospitals delivered a strong financial performance in the first quarter, reporting a 42% year-on-year increase in net profit to Rs 433 crore. The hospital chain’s growth was driven by a combination of higher patient volumes, operational efficiencies, and an expanding portfolio of specialty services. Revenue growth was supported by the steady recovery in elective procedures and growing demand for digital healthcare solutions.

Fortis Healthcare delivered an impressive financial performance in the first quarter of FY26, reporting a 57% year-on-year increase in consolidated net profit. The company attributed this growth to improved operational metrics, higher occupancy rates, and strategic cost controls. Revenues also witnessed a healthy rise, backed by a robust performance in the hospital and diagnostics segments.

Procter & Gamble Hygiene and Health Care Ltd. (P&G Hygiene) delivered a robust financial performance in the second quarter, with net profit soaring over twofold to Rs. 192 crore. The surge was driven by higher volumes, improved product mix, and disciplined cost controls. Revenue from operations climbed steadily, underlining the resilience of consumer demand despite inflationary headwinds. The company’s strong performance in its core categories of feminine hygiene and healthcare products reflects strategic pricing and brand loyalty.

The Adani Group has unveiled a sweeping plan to develop an “AI-first” healthcare ecosystem across India, marking a significant pivot into one of the nation’s most critical and under-resourced sectors. By embedding artificial intelligence throughout the continuum of care — from predictive diagnostics to precision treatment and long-term wellness management — Adani aims to address the dual challenges of accessibility and quality that have long plagued India’s healthcare system.

Apollo AyurVAID, the Ayurveda-focused arm of the Apollo Hospitals Group, has announced its official entry into the consumer Ayurveda products segment, marking a significant expansion beyond its established chain of integrative care hospitals and clinics. This strategic move positions Apollo to tap into India’s burgeoning Rs. 1,000 crore-plus Ayurveda consumer market, driven by rising demand for natural health solutions and preventive wellness.